207 related articles for article (PubMed ID: 25210554)
1. Application of bone scans for prostate cancer staging: Which guideline shows better result?
Chong A; Hwang I; Ha JM; Yu SH; Hwang EC; Yu HS; Kim SO; Jung SI; Kang TW; Kwon DD; Park K
Can Urol Assoc J; 2014 Jul; 8(7-8):E515-9. PubMed ID: 25210554
[TBL] [Abstract][Full Text] [Related]
2. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of a novel risk stratification tool.
De Nunzio C; Leonardo C; Franco G; Esperto F; Brassetti A; Simonelli G; Dente D; De Dominicis C; Tubaro A
World J Urol; 2013 Apr; 31(2):365-9. PubMed ID: 22576696
[TBL] [Abstract][Full Text] [Related]
3. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
4. Development of a nomogram predicting metastatic disease and the assessment of NCCN, AUA and EAU guideline recommendations for bone imaging in prostate cancer patients.
Ma MW; Gao XS; Lyu F; Gu XB; Yin H; Li HZ; Li XY; Qi X; Bai Y; Chen JY
World J Urol; 2021 Jun; 39(6):1815-1823. PubMed ID: 32691147
[TBL] [Abstract][Full Text] [Related]
5. Population-Based Comparison of Different Risk Stratification Systems Among Prostate Cancer Patients.
Xie M; Gao XS; Ma MW; Gu XB; Li HZ; Lyu F; Bai Y; Chen JY; Ren XY; Liu MZ
Front Oncol; 2021; 11():646073. PubMed ID: 33928035
[TBL] [Abstract][Full Text] [Related]
6. When to perform bone scan in patients with newly diagnosed prostate cancer: external validation of the currently available guidelines and proposal of a novel risk stratification tool.
Briganti A; Passoni N; Ferrari M; Capitanio U; Suardi N; Gallina A; Da Pozzo LF; Picchio M; Di Girolamo V; Salonia A; Gianolli L; Messa C; Rigatti P; Montorsi F
Eur Urol; 2010 Apr; 57(4):551-8. PubMed ID: 20034730
[TBL] [Abstract][Full Text] [Related]
7. Is pelvic MRI imaging sufficient cross-sectional imaging for staging intermediate and high-risk prostate cancer?
Grant Owens R; Loloi J; Lehman EB; Kaag MG; Raman JD; Merrill SB
Urol Oncol; 2021 Jul; 39(7):433.e9-433.e15. PubMed ID: 33610444
[TBL] [Abstract][Full Text] [Related]
8. [Necessity analysis of bone scan in patients with newly diagnosed prostate cancer].
Zhou JQ; Zhu Y; Yao XD; Zhang SL; Dai B; Zhang HL; Ye DW
Zhonghua Yi Xue Za Zhi; 2013 Jan; 93(4):248-51. PubMed ID: 23578501
[TBL] [Abstract][Full Text] [Related]
9. Establishing the pathways and indications for performing isotope bone scans in newly diagnosed intermediate-risk localised prostate cancer - results from a large contemporaneous cohort.
KandaSwamy GV; Bennett A; Narahari K; Hughes O; Rees J; Kynaston H
BJU Int; 2017 Nov; 120(5B):E59-E63. PubMed ID: 28317247
[TBL] [Abstract][Full Text] [Related]
10. Toward better use of bone scans among men with early-stage prostate cancer.
Merdan S; Womble PR; Miller DC; Barnett C; Ye Z; Linsell SM; Montie JE; Denton BT
Urology; 2014 Oct; 84(4):793-8. PubMed ID: 25096341
[TBL] [Abstract][Full Text] [Related]
11. Determination of the optimal cut-off value of serum prostate-specific antigen in the prediction of skeletal metastases on technetium-99m whole-body bone scan by receiver operating characteristic curve analysis.
Manohar PR; Rather TA; Khan SH
World J Nucl Med; 2020; 19(3):255-259. PubMed ID: 33354181
[TBL] [Abstract][Full Text] [Related]
12. [Predictive value of prostate-specific antigen and Gleason sum for results of radionuclide bone scintigraphy in patients with prostate cancer].
Wang TY; Chen XP; Li XS; Jia Yx; Cheng J; Zhang JH; Cai L; Zhang Z; Gong K; He ZS; Zhou LQ
Beijing Da Xue Xue Bao Yi Xue Ban; 2012 Aug; 44(4):528-34. PubMed ID: 22898839
[TBL] [Abstract][Full Text] [Related]
13. A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings.
Luzzago S; de Cobelli O; Cozzi G; Peveri G; Bagnardi V; Catellani M; Di Trapani E; Mistretta FA; Pricolo P; Conti A; Alessi S; Marvaso G; Ferro M; Matei DV; Renne G; Jereczek-Fossa BA; Petralia G; Musi G
BJU Int; 2020 Jul; 126(1):104-113. PubMed ID: 32150328
[TBL] [Abstract][Full Text] [Related]
14. Bone scan can be spared in asymptomatic prostate cancer patients with PSA of <=20 ng/ml and Gleason score of <=6 at the initial stage of diagnosis.
Tanaka N; Fujimoto K; Shinkai T; Nakai Y; Kuwada M; Anai S; Miyake M; Hirayama A; Hasegawa M; Hirao Y
Jpn J Clin Oncol; 2011 Oct; 41(10):1209-13. PubMed ID: 21862505
[TBL] [Abstract][Full Text] [Related]
15. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
16. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
[TBL] [Abstract][Full Text] [Related]
17. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital.
O'Sullivan JM; Norman AR; Cook GJ; Fisher C; Dearnaley DP
BJU Int; 2003 Nov; 92(7):685-9. PubMed ID: 14616446
[TBL] [Abstract][Full Text] [Related]
18. Can initial prostate specific antigen determinations eliminate the need for bone scans in patients with newly diagnosed prostate carcinoma? A multicenter retrospective study in Japan.
Kosuda S; Yoshimura I; Aizawa T; Koizumi K; Akakura K; Kuyama J; Ichihara K; Yonese J; Koizumi M; Nakashima J; Fujii H
Cancer; 2002 Feb; 94(4):964-72. PubMed ID: 11920464
[TBL] [Abstract][Full Text] [Related]
19. Predicting Prostate Cancer Death with Different Pretreatment Risk Stratification Tools: A Head-to-head Comparison in a Nationwide Cohort Study.
Zelic R; Garmo H; Zugna D; Stattin P; Richiardi L; Akre O; Pettersson A
Eur Urol; 2020 Feb; 77(2):180-188. PubMed ID: 31606332
[TBL] [Abstract][Full Text] [Related]
20. Changing the referral criteria for bone scan in newly diagnosed prostate cancer patients.
McArthur C; McLaughlin G; Meddings RN
Br J Radiol; 2012 Apr; 85(1012):390-4. PubMed ID: 21304009
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
